Strive, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 16, 2026, details the completion of the merger between Strive, Inc. ("Strive") and Semler Scientific, Inc. ("Semler Scientific"). Following the merger, Semler Scientific continues as a wholly-owned subsidiary of Strive. The filing also covers the entry into a supplemental indenture regarding Semler Scientific's outstanding debt, changes to the Board of Directors, and the approval of a new equity incentive plan.
Key Financial Metrics and Debt Obligations
The filing focuses on the restructuring of debt obligations rather than reporting period-specific revenue or profit metrics. Key financial terms include:
- Outstanding Debt: $100 million aggregate principal amount of 4.25% Convertible Senior Notes due 2030 remains outstanding.
- Interest Rate: 4.25% per year, payable semiannually on February 1 and August 1.
- Maturity Date: August 1, 2030.
- Guarantee: The Notes are now guaranteed by Strive, Inc.
- Conversion Terms: The conversion rate was adjusted to 275.3887 shares of Strive Common Stock per $1,000 principal amount of Notes. Based on the initial maximum conversion rate, 34,423,480 shares of Strive Common Stock are initially issuable upon conversion.
- Merger Consideration: Each share of Semler Common Stock was converted into the right to receive 21.05 shares of Strive Common Stock.
Note: The filing text does not provide clear values for revenue, net profit, operating cash flow, or liquidity ratios for the reporting period.
Material Changes Versus Prior Period
The primary material change is the corporate structure resulting from the Merger:
- Debt Restructuring: The right to convert Semler Scientific's Notes into Semler Common Stock was replaced with the right to convert into Strive Common Stock.
- Board Composition: Avik Roy resigned from the Board of Directors to become Chief Strategy Officer. Eric Semler was appointed to fill the vacancy as a Class II director.
- Equity Plan: The 2026 Omnibus Equity Incentive Plan was approved, authorizing the issuance of shares equal to the remaining availability under the prior plan plus 110,789,280 new shares.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing confirms the successful integration of Semler Scientific into Strive. The new equity plan is designed to motivate employees and directors to contribute to Strive's success.
Risks and Contingencies: The Supplemental Indenture outlines specific events of default that could accelerate the debt, including:
- Failure to pay interest or principal when due.
- Failure to comply with conversion obligations.
- Default on other indebtedness exceeding $15.0 million.
- Bankruptcy or insolvency events involving Strive or Semler Scientific.
- Redemption Rights: Semler Scientific may redeem the Notes on or after August 4, 2028, if Strive's stock price exceeds 130% of the conversion price for a specified period.
- Fundamental Change Repurchase: If Strive undergoes a fundamental change, holders may require a cash repurchase of the Notes at 100% of principal plus accrued interest.
Key Facts for Investor Verification
- Verify the adjusted conversion rate of 275.3887 shares of Strive Common Stock per $1,000 of Notes and the potential dilution of 34,423,480 shares.
- Confirm the $100 million principal amount of debt now guaranteed by Strive and its impact on the consolidated balance sheet.
- Review the terms of the 2026 Omnibus Equity Incentive Plan, specifically the 110,789,280 share increase and the annual automatic increase mechanism.
- Monitor the redemption conditions for the Notes, which become exercisable by the issuer after August 4, 2028.
- Check the effective date of the Board elections and Plan approval, which is 20 days from the mailing of the definitive Information Statement.